CN101686966A - 使用生长激素促分泌素治疗细胞增生疾病的方法 - Google Patents

使用生长激素促分泌素治疗细胞增生疾病的方法 Download PDF

Info

Publication number
CN101686966A
CN101686966A CN200880011801A CN200880011801A CN101686966A CN 101686966 A CN101686966 A CN 101686966A CN 200880011801 A CN200880011801 A CN 200880011801A CN 200880011801 A CN200880011801 A CN 200880011801A CN 101686966 A CN101686966 A CN 101686966A
Authority
CN
China
Prior art keywords
alkyl
aryl
independently
hydrogen
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880011801A
Other languages
English (en)
Chinese (zh)
Inventor
W·J·波维诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Therapeutics US Inc
Original Assignee
Helsinn Therapeutics US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Therapeutics US Inc filed Critical Helsinn Therapeutics US Inc
Publication of CN101686966A publication Critical patent/CN101686966A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN200880011801A 2007-02-13 2008-02-08 使用生长激素促分泌素治疗细胞增生疾病的方法 Pending CN101686966A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90160907P 2007-02-13 2007-02-13
US60/901,609 2007-02-13
PCT/US2008/001748 WO2008100448A2 (en) 2007-02-13 2008-02-08 Method of treating cell proliferative disorders using growth hormone secretagogues

Publications (1)

Publication Number Publication Date
CN101686966A true CN101686966A (zh) 2010-03-31

Family

ID=39690677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880011801A Pending CN101686966A (zh) 2007-02-13 2008-02-08 使用生长激素促分泌素治疗细胞增生疾病的方法

Country Status (12)

Country Link
US (1) US20080207640A1 (enExample)
EP (1) EP2134341B1 (enExample)
JP (1) JP2010518158A (enExample)
KR (1) KR20090112720A (enExample)
CN (1) CN101686966A (enExample)
AU (1) AU2008216789A1 (enExample)
CA (1) CA2677813A1 (enExample)
EA (1) EA200970764A1 (enExample)
IL (1) IL200367A0 (enExample)
MX (1) MX2009008561A (enExample)
TW (1) TWI450719B (enExample)
WO (1) WO2008100448A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107205389A (zh) * 2014-09-04 2017-09-26 赫尔辛医疗股份公司 基于阿拉莫林的药物治疗
CN110041304A (zh) * 2012-04-20 2019-07-23 赫尔森保健股份公司 制备具有受控氯化物含量的阿拉莫林盐酸盐的方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011105611A1 (ja) * 2010-02-26 2013-06-20 ラクオリア創薬株式会社 悪液質を治療するためのグレリン受容体作動物質
CN111557432B (zh) 2013-02-08 2023-08-04 通用磨坊公司 低钠食品
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US20220323430A1 (en) 2019-08-30 2022-10-13 Helsinn Healthcare Sa Methods of manufacturing anamorelin tablets having improved stability
AU2020394867A1 (en) 2019-12-02 2022-05-26 Storm Therapeutics Limited Polyheterocyclic compounds as METTL3 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2179597A1 (en) * 1993-12-23 1995-06-29 Nils Langeland Johansen Compounds with growth hormone releasing properties
AU715856B2 (en) * 1995-12-22 2000-02-10 Novo Nordisk A/S Compounds with growth hormone releasing properties
JP4425992B2 (ja) * 1996-07-22 2010-03-03 サファイア セラピューティクス，インコーポレイティド 成長ホルモン放出特性を有する化合物
US6566334B1 (en) * 1997-02-06 2003-05-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Short amphipathic peptides with activity against bacteria and intracellular pathogens
US6286927B1 (en) * 1997-12-25 2001-09-11 Canon Kabushiki Kaisha Ink jet element substrate and ink jet head that employs the substrate, and ink jet apparatus on which the head is mounted
US6494563B2 (en) * 1997-12-25 2002-12-17 Canon Kabushiki Kaisha Ink jet element substrate and ink jet head that employs the substrate, and ink jet apparatus on which the head is mounted
US6083908A (en) * 1998-01-16 2000-07-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6124263A (en) 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6566337B1 (en) * 1998-11-03 2003-05-20 Novo Nordisk A/S Compounds with growth hormone releasing properties
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
EP1159964B1 (en) * 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
AU8180001A (en) * 2000-06-07 2001-12-17 Applied Research Systems Human growth hormone to stimulate mobilization of pluripotent hematopoietic stemcells
JP2005511475A (ja) * 2001-03-02 2005-04-28 ブリストル−マイヤーズ スクイブ カンパニー メラノコルチン受容体のモジュレーターとして有用な化合物及びそれを含む製薬組成物
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
JP2007531769A (ja) * 2004-03-30 2007-11-08 サファイア セラピューティクス インコーポレイテッド 成長ホルモン分泌促進薬を使用したｃ−反応性蛋白質の低減方法
CN101657436A (zh) * 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110041304A (zh) * 2012-04-20 2019-07-23 赫尔森保健股份公司 制备具有受控氯化物含量的阿拉莫林盐酸盐的方法
CN107205389A (zh) * 2014-09-04 2017-09-26 赫尔辛医疗股份公司 基于阿拉莫林的药物治疗

Also Published As

Publication number Publication date
EA200970764A1 (ru) 2010-04-30
CA2677813A1 (en) 2008-08-21
EP2134341A4 (en) 2011-08-17
EP2134341A2 (en) 2009-12-23
AU2008216789A1 (en) 2008-08-21
JP2010518158A (ja) 2010-05-27
TW200914019A (en) 2009-04-01
EP2134341B1 (en) 2015-06-17
KR20090112720A (ko) 2009-10-28
TWI450719B (zh) 2014-09-01
US20080207640A1 (en) 2008-08-28
WO2008100448A2 (en) 2008-08-21
MX2009008561A (es) 2010-01-15
IL200367A0 (en) 2010-04-29
WO2008100448A3 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
TWI450719B (zh) 使用生長激素促泌素於製造治療癌症惡病質之醫藥組成物之用途
US20020128228A1 (en) Compositions and methods for the treatment of cancer
US20040072824A1 (en) Methods and compositions for the treatment of cancer
US8318737B2 (en) Compounds and compositions for treating cancer
CN110325542A (zh) 克罗拉滨的前体药物
US20180098975A1 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
TWI721136B (zh) 特定苯並二氫呋喃類木脂素於抑制乳癌細胞轉移之用途
US9839632B2 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
US9018171B2 (en) Uses of an immunomodulatory protein (GMI) from Ganoderma microsporum
AU2015362720A1 (en) Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo(b)azepine-4-carboxamide, compositions thereof, and uses thereof
WO2004080445A1 (en) Methods and compositions for the treatment of cancer
US20120157455A1 (en) Compounds And Compositions For Treating Cancer
AU2010289493A1 (en) Compounds and compositions for treating cancer
US20070270448A1 (en) Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders
WO2004065572A2 (en) Proteic binding partners of tctp and methods of modulating tumor reversion or cell apoptosis
US20250099414A1 (en) Compositions and methods for treating triple-negative breast cancer
WO2008036954A1 (en) Use of n- [5- [ [ [5- (1, 1-dimethylethyl) -2-oxazoyl] methyl] thio] -2-thiazolyl] -4-piperidinecarboxamide
KR20090061358A (ko) 아카세틴을 유효성분으로 하는 유방암 예방 및 치료용조성물
TW202428876A (zh) 治療難治型腦瘤之方法
WO2007143096A2 (en) Compounds for treating cancers
CA2845095A1 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
KR20050016439A (ko) 질환-관련 쇠약증을 치료 또는 예방하기 위한 ｊｎｋ억제제를 사용하는 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20100331